AJMC lays out five implications of retatrutide biologic classification
The piece walks through what regulatory status as a biologic would mean for the experimental incretin's approval and follow-on competition pathway.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 7 15:28 ETSource: AJMC
The wire
- 01AJMC published a five-point explainer on what would change if retatrutide were classified as a biologic rather than a small-molecule or conventional peptide drug.
- 02Classification drives the approval route, exclusivity and whether follow-on versions arrive as biosimilars, which matters to pharmacists and telehealth operators planning supply.
- 03The classification question remains open, and the piece is an analysis rather than an agency decision on retatrutide.
From the source
Read at ajmc.com5 Things to Know if Retatrutide Is Classified as a Biologic
